Immunome

Immunome, Inc. is a clinical-stage biotechnology company based in Exton, Pennsylvania, focused on developing targeted cancer therapies. The company utilizes a unique immunotherapy discovery platform that explores the human immune system, particularly the memory B-cell response, to identify new cancer targets and patient-derived antibodies with therapeutic potential. Immunome is publicly traded on NASDAQ under the ticker symbol IMNM. The company specializes in antibody-drug conjugates (ADCs) and other immunotherapies designed to harness the immune system in the fight against cancer. Its pipeline includes Varegacestat, currently in Phase 3 trials for desmoid tumors, and IM-1021, a ROR1-targeted ADC in Phase 1 trials. Additionally, IM-3050, a fibroblast activation protein-targeted radioligand, has received IND clearance, along with several preclinical ADC candidates targeting various solid tumors. Immunome aims to improve cancer treatment outcomes by delivering innovative therapies that address significant unmet medical needs.